Luminex
Diasorin Nabs FDA 510(k) Clearance for Expanded Respiratory Panel
The firm said that its NxTag Respiratory Pathogen Panel v2 adds detection of the SARS-CoV-2 virus for a total of 21 viral and bacterial targets.
Streck Quality Controls for DiaSorin's Luminex Sepsis Tests Receive FDA Clearance
The quality controls are designed to verify the performance of the Luminex Verigene Blood Culture Gram-Positive and Gram-Negative tests.
Decline in DiaSorin's Q2 MDx Revenues Offset by Strength in Immunodiagnostics
Non-COVID-19 immunodiagnostics revenues drove an otherwise strong quarter for DiaSorin with continued growth in North America and Europe and slow improvement in China.
DiaSorin Q1 Revenues Fall 19 Percent on COVID Sales Decline
A 78 percent decline in COVID testing revenues was partially offset by revenue growth in its other diagnostics businesses.
DiaSorin 2022 Revenues Grow 10 Percent
For 2023, total revenues are expected to decline 14 percent year over year, and COVID-19 revenues are expected to be down 75 percent to €60 million.
Sep 9, 2022
Jul 9, 2021